Tiventures SA

📰 Today we are happy to announce the closing of our €36 million [$40M] round, the biggest European smart farming Series C funding round. 🤝 The round is led by Partech with its Impact fund, with participation from Mouro Capital, a FinTech vertical firm. 🖋️ Swisscom Ventures, United Ventures, and all previous institutional investors also participated in the round, demonstrating their confidence in xFarm Technologies based on its significant achievements over the past two years. 🚀 Seven years after the foundation of xFarm and two years after the Series B funding round, it is great to get such significant support from old and new investors. 📈 We intend to use the capital raised to consolidate our leadership in Europe and accelerate our expansion throughout the rest of the continent, as well as in LATAM, India, Turkey, and the US. 👨🌾 We are stronger now, and together with our investors, partners, and clients, we intend to improve our performance, develop our AI, Regenerative Agriculture, and FinTech services further, and tailor them to the needs of specific markets and customers. 📜 During the whole operation, we had the legal support of Bär & Karrer. 👉 Check out the news on Sifted https://lnkd.in/dn88hCtM #xFarmTechnologies #xFarm #RoundC

More amazing preclinical data presented by Gain Therapeutics at the Society for Neuroscience 2024 conference in Chicago. In three different posters, the lead clinical candidate GT-02287 has been shown to rescue motor and cognitive function in animal models of #Parkinson’s disease even one week after discontinuation of treatment. In a similar in vivo model, GT-02287 also significantly improved mitochondrial dysfunction and neurodegeneration. Finally, GT-02287 was shown in vitro to reduce accumulation of Tau, suggesting a potential application also for #Alzheimer’s disease. These results, together with the results obtained in the first clinical trial that indicated GCase target engagement, suggest that GT-02287 may be able in the future to provide relief not only to #Parkinson’s disease patients but also to other #neurodegenerative diseases. Congratulations to everybody at Gain Therapeutics involved in the presented data and the development of GT-02287.

I would like to thank all attendees of our event on #VentureCapital at the LAC Lugano Arte e Cultura. We had a great time listening to the speakers, which included Laurent Frésard of USI Università della Svizzera italiana who provided the reasons why venture capital should be part of all asset allocation strategies. Alexander Schlaepfer of Swisscom Ventures provided an update of the relevance of VC for Switzerland and how Swisscom Ventures operates. Louis Fauchier-Magnan presented the reasons why Mirabaud Group has decided to invest in Swiss VCs. Finally, Dario My provided an update on Deep Tech Nation Switzerland and the new "superfund" that is in preparation and that will be a game-changer for the startup and VC ecosystem. A special thank to Tina Willibald, Paolo Orsatti, Attilio B. and Martina Cossutti for the help in the organization.

I voted for Artificialy SA to win the TOP 100 Swiss Startup Public Vote 2024! Vote too www.startup.ch/artificialy via @venturelab_ch #TOP100SSU

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease https://lnkd.in/erYhDpu5

Allego un articolo apparso oggi sul Corriere del Ticino, scritto insieme a Donatella Negrini e Marco Bernasconi, sul tema della valutazione dei titoli non quotati ai fini dell'imposta sulla sostanza.

Silvia Coco sta #assumendo. Conosci qualcuno a cui potrebbe interessare?